ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Dr Matteo Lambertini provides ecancer with a roundup of the most important breast cancer research from ESMO 2021.
Dr Lambertini provides detailed information on the following trials:
| DESTINY-Breast03 trial | |
| TULIP Study | |
| MONALEESA-2 Trial | |
| KEYNOTE-355 Trial | |
| BrighTNess Trial | |
| GIM4 Trial | |
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Highlights and analysis
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Management of HER2 positive metastatic breast cancer treatment algorithm